As of July 2017, it is marketed under many brand names worldwide: Allersoothe, Antiallersin, Anvomin, Atosil, Avomine, Closin N, Codopalm, Diphergan, Farganesse, Fenazil, Fenergan, Fenezal, Frinova, Hiberna, Histabil, Histaloc, Histantil, Histazin, Histazine, Histerzin, Lenazine, Lergigan, Nufapreg, Otosil, Pamergan, Pharmaniaga, Phenadoz, Phenerex, Phenergan, Phénergan, Pipolphen, Polfergan, Proazamine, Progene, Prohist, Promet, Prometal, Prometazin, Prometazina, Promethazin, Prométhazine, Promethazinum, Promethegan, Promezin, Proneurin, Prothazin, Prothiazine, Prozin, Pyrethia, Quitazine, Reactifargan, Receptozine, Romergan, Sominex, Sylomet, Vertigon, Xepagan, Zinmet, and Zoralix.
Product liability lawsuit In 2009, the
US Supreme Court ruled on a
product liability case involving promethazine. Diana Levine, a woman with a migraine, was administered
Wyeth's Phenergan via
IV push. The drug was injected improperly, resulting in
gangrene and subsequent amputation of her right forearm below the elbow. A state jury awarded her $6 million in
punitive damages. The case was appealed to the Supreme Court on grounds of
federal preemption and
substantive due process. The Supreme Court upheld the lower courts' rulings, stating that "Wyeth could have unilaterally added a stronger warning about IV-push administration" without acting in opposition to federal law. In effect, this means drug manufacturers can be held liable for injuries if warnings of potential adverse effects, approved by the
US Food and Drug Administration (FDA), are deemed insufficient by state courts. In September 2009, the FDA required a
boxed warning be put on promethazine for injection, stating the contraindication for subcutaneous administration. The preferred administrative route is intramuscular, which reduces the risk of surrounding muscle and tissue damage. == References ==